We hence examined RB1/TP53 co-mutation pattern by both vital status and sample type in these breast cancer types (Figure 3b) and found that the death association of RB1/TP53 co-mutation is much more prominent in primary cancer samples than in metastatic samples, suggesting RB1/TP53 co-mutation confers a more aggressive disease and account for more deaths in primary breast cancer. This evidence concerns the gene RB1 and breast cancer.